|

KST-6051 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Kestrel Therapeutics, Inc.1

Indications

  • Other KRAS-mutant Solid Tumors1
  • KRAS-mutant Colorectal Cancer (CRC)1
  • KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)1
  • KRAS-mutant Non-small Cell Lung Cancer (NSCLC)1
  • Lung Cancer1

San Antonio, Texas1 trial

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

NEXT Oncology

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.